Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;75(1):251-254.
doi: 10.1016/j.jhep.2021.02.024. Epub 2021 Feb 27.

Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings

Michelle T Martin  1 , Sonalie Patel  2 , Laura Kulik  2 , Christine Chan  3
Affiliations
Comment

Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings

Michelle T Martin et al. J Hepatol. 2021 Jul.
No abstract available

Keywords: direct-acting antivirals; glecaprevir/pibrentasvir; hepatitis C virus; retreatment; ribavirin; salvage therapy; sofosbuvir.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest CC does not have any conflicts of interest to disclose. LK serves on the advisory board for Bayer, Eisai, Exelixis, Genentech, Gilead and Merck; is on the speakers’ bureau for Bayer, Gilead and Peer View CME; and is a researcher for Target-HCC. MM serves on the speakers’ bureau for AbbVie, has received grant funding from Gilead and Merck, served on the advisory board for AbbVie and Gilead, and is a minor shareholder of AbbVie, Gilead, and Merck stock. SP serves on the speakers’ bureau for AbbVie. Please refer to the accompanying ICMJE disclosure forms for further details.

Comment in

Comment on

  • Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
    Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer AE, Lara M, Pardo MR, Zoller H, Degasperi E, Peiffer KH, Sighinolfi L, Téllez F, Graf C, Ghisetti V, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, García F, Sarrazin C; HCV Virology Italian Resistance Network (VIRONET-C) collaborators; Spanish GEHEP-004 Collaborators; Members of the German HCV resistance study group. Dietz J, et al. J Hepatol. 2021 Apr;74(4):801-810. doi: 10.1016/j.jhep.2020.11.017. Epub 2020 Nov 19. J Hepatol. 2021. PMID: 33220331

LinkOut - more resources